Topics

Videos

Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the key takeaways of this year's keynote speech. 

Access Insights 2024: Financial Headwinds and Tailwinds to Commercialization

Articles

The session dives into the obstacles surrounding data usability, mandate compliance, initial adoption, and limitations in this arena. 

Access Insights 2024: Analyzing Drug Pricing and Reimbursement Data Amid a New Wave of CMS Price Requirements 

The conference’s opening keynote sets the scene for 2025 and the years to come. 

Access Insights 2024: Commercialization’s Financial Headwinds and Tailwinds

Podcasts

Steve Silvestro explains the value of artificial intelligence in launch plans, benefits to integrating DTC and HCP marketing strategies, and more. 

Incorporating AI into Commercialization Plans

Why this trend is occurring and ways that drugmakers are pivoting in order to remedy the situation.

Who Moved My Prescription? Part VI: Abandonment of Branded Prescriptions

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it. 

Xofluza Significantly Reduces Household Influenza Transmission 

It’s essential for commercial success, but presents its share of obstacles.

Beyond the Finish Line: Why Post-Approval Regulatory Strategy Matters

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab. 

GSK’s Depemokimab Significantly Reduces Asthma Exacerbations 

This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization. 

Pharma KOLs to Unite at Access Insights Conference 2024

ROCTAVIAN will only be sold to the United States, Italian, and German markets, as the company eyes its profitability by 2025. 

Commercial Channels